Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNI61P
|
|||
| Drug Name |
CP101
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Autism spectrum disorder [ICD-11: 6A02; ICD-10: F84.0; ICD-9: 299] | Phase 2 | [1] | |
| Clostridium infection [ICD-11: 1A04; ICD-10: A04.7] | Phase 2 | [2] | ||
| Company |
Finch Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | N-methyl-D-aspartate receptor (NMDAR) | Target Info | Antagonist | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03829878) Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) (SPROUT). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03497806) Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT). U.S. National Institutes of Health. | |||
| REF 3 | The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma. 1997 Jun;14(6):409-17. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.